Table 2.
Comparison between MIS-C patients in Japan and other regions.
| This Case | MIS-C in Japan (n= 4) [[20], [21], [22], [23]] Median [range] | MIS-C in the worlda (n= 917) [8] Average (95% CI) | |
|---|---|---|---|
| Age at onset | 15 | 9.5 [[9], [10], [11], [12], [13], [14], [15], [16]] | 9.3 (8.4–10.1) |
| Sex, Male (%) | Male | 50 | 56.8 (52.1–61.5) |
| Clinical symptoms | |||
| Complete KD (%) | + | 75 | 44.3 (34.7–53.9) |
| Gastrointestinal (%) | + | 100 | 87.3 (82.9–91.6) |
| Neurologic (%) | + | 25 | 36.0 (22.8–49.2) |
| Cardiovascular (%) | – | 75 | 55.3 (42.4–68.2) |
| Laboratory values | |||
| White blood cell ( × 109/L) | 4.3 | 11.9 [8.8–14.1] | 11.8 (10.5–13.2) |
| Lymphocyte count ( × 109/L) | 0.17 | 0.26 [0.11–0.51] | 0.8 (0.7–1.0) |
| Platelet count ( × 109/L) | 49 | 144 [74–315] | 155.1 (143.2–167.1) |
| C-reactive protein (mg/dL) | 10.2 | 21.3 [19.2–23.0] | 23.5 (21.6–25.6) |
| Ferritin (ng/mL) | 11,404 | 909.5 [294–3685] | 711.0 (599.5–822.4) |
| d-Dimer (μg/mL) | 13.0 | 9.45 [3.6–24.3] | 3.5 (2.9–4.1) |
| Brain natrium peptide (pg/mL) | 46.4 | 599 [104–1271] | 2191.5 (1334.2–3048.7) |
| Treatment | |||
| Intravenous immunoglobulin (%) | + | 100 | 81.0 (75.0–86.9) |
| Corticosteroids (%) | + | 50 | 63.6 (53.4–73.8) |
| Aspirin (%) | + | 50 | 67.3 (48.8–85.7) |
| Infliximab (%) | + | 0 | 8.0 (2.9–13.1) |
| Mechanical ventilation (%) | – | 0 | 33.0 (24.5–41.5) |
| ECMO (%) | – | 0 | 6.3 (2.8–9.8) |
| Outcomes | |||
| ICU admission (%) | – | 25 | 79.1 (71.6–86.7) |
| Shock (%) | – | 25 | 65.8 (51.1–80.4) |
| Death (%) | – | 0 | 1.9 (1.0–2.8) |
| Coronary artery dilation or aneurysm (%) | – | 25 | 21.4 (12.8–30.1) |
MIS-C, multisystem inflammatory syndrome in children; KS, Kawasaki disease; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation.
a
Twelve studies were conducted in the United States, United Kingdom, France, Italy and Spain.